KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Return on Equity: 2009-2025

Historic Return on Equity for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to 0.09%.

  • Biomarin Pharmaceutical's Return on Equity rose 3.00% to 0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.09%, marking a year-over-year increase of 3.00%. This contributed to the annual value of 0.08% for FY2024, which is 5.00% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Return on Equity of 0.09% as of Q3 2025, which was down 22.54% from 0.11% recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Return on Equity registered a high of 0.20% during Q2 2021, and its lowest value of -0.02% during Q4 2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median Return on Equity value was 0.05% (recorded in 2024), while the average stood at 0.06%.
  • The largest annual percentage gain for Biomarin Pharmaceutical's Return on Equity in the last 5 years was 16bps (2021), contrasted with its biggest fall of 23bps (2021).
  • Over the past 5 years, Biomarin Pharmaceutical's Return on Equity (Quarterly) stood at -0.02% in 2021, then grew by 5bps to 0.03% in 2022, then remained steady at 0.03% in 2023, then grew by 4bps to 0.08% in 2024, then grew by 3bps to 0.09% in 2025.
  • Its Return on Equity was 0.09% in Q3 2025, compared to 0.11% in Q2 2025 and 0.09% in Q1 2025.